m6A-mediated silencing of RNF41 by METTL3/YTHDC1 disrupts autophagy to drive intervertebral disc degeneration
摘要
Intervertebral disc (IVD) degeneration (IDD) represents a predominant origin of low back pain and disability, yet current therapeutic interventions remain suboptimal. Emerging evidence highlights autophagy activation as a therapeutic strategy against IDD. This study investigates the mechanistic interplay between N6-methyladenosine (m6A) modifications and autophagy dysregulation in IDD pathogenesis.
MethodsBioinformatics analysis identified ring finger protein 41 (RNF41) as a key autophagy-IDD intersection gene. Functional validation utilized tert-butyl hydroperoxide (TBHP)-treated human nucleus pulposus (NP) cells to assess RNF41’s effects on senescence (CDKN2A), autophagy (LC3-II/p62), apoptosis (TUNEL), inflammation (IL-18/IL-1β), and extracellular matrix (ECM) homeostasis (aggrecan/MMP). Key m6A regulators modulating autophagy were screened via correlation analysis. In vivo validation employed adeno-associated virus (AAV)-mediated methyltransferase-like 3 (METTL3)/RNF41 delivery in puncture-induced IDD rat models.
ResultsRNF41 expression was downregulated in human IVD tissues. Overexpression of RNF41 mitigated TBHP-induced senescence, apoptosis, activated AMPK/mTOR-mediated autophagy, suppressed inflammation, and restored ECM balance. The autophagy inhibitor chloroquine (CQ) abolished the protective effects of RNF41 overexpression on degenerative NP cells. Mechanistically, METTL3/YTHDC1 co-regulation in degenerative NP cells mediated m6A hypermethylation of RNF41 mRNA, shortening its half-life via YTHDC1-dependent decay. Intradiscal METTL3-silencing AAV attenuated puncture-induced disc loss and histopathological degeneration, whereas RNF41-silencing AVV exacerbated ECM disruption and annular disorganization.
ConclusionMETTL3/YTHDC1-mediated m6A modification drives IDD progression by silencing RNF41, thereby impairing autophagy and ECM integrity. Targeting this axis offers a clinically actionable strategy to delay disc degeneration, particularly in patients with early-stage IDD. This evidence establishes RNF41’s role as a theragnostic biomarker and therapeutic targe, enabling precision-guided interventional approaches.